CNS or classic drugs for the treatment of pain in functional dyspepsia? A systematic review and meta-analysis of the literature.

BACKGROUND Recent evidence has suggested that pain in functional dyspepsia (FD) is associated with nervous system dysfunction; indicating that therapies aimed at nervous system modulation might be associated with pain relief in FD. OBJECTIVE To conduct a systematic review and meta-analysis to quantify the efficacy of drugs targeting the central nervous system (antidepressants and antianxiety agents - referred as "CNS drugs") and drugs targeting gastric modulation (antisecretory and prokinetic - referred as "classic drugs") for the treatment of pain in FD and, in an exploratory way, compare these 2 modalities of treatment. METHODS MEDLINE and reference lists were examined for relevant articles. We included prospective studies that evaluated the effects of either CNS drugs or classic drugs (subdivided in prokinetic and antisecretory drugs) on the symptoms of FD. RESULTS Seven studies for CNS drugs and 11 studies for gastric drugs met our inclusion criteria. The analyses of these drugs showed that the 2 groups of drugs are associated with a significant reduction in dyspeptic symptoms. The pooled effect size (standardized mean difference between pre-treatment versus post-treatment means) from the random effects model was 1.25 (95% C.I., 0.83, 1.67) for CNS; 1.63 (95% C.I., 1.28, 1.97) for prokinetic, and 0.93 (95% C.I., 0.57, 1.29) for antisecretory drugs. The exploratory comparison between classes of drugs revealed no significant difference in dyspeptic symptoms reduction between CNS and prokinetic drugs; however CNS drugs were associated with a larger reduction in symptoms as compared with antisecretory drugs. CONCLUSIONS The results show that both CNS and classic drugs are associated with a significant pain reduction in functional dyspepsia.

[1]  M. Camilleri GASTROENTEROLOGY CLINICS OF NORTH AMERICA Functional Dyspepsia : Mechanisms of Symptom Generation and Appropriate Management of Patients , 2022 .

[2]  J. Tack,et al.  Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[3]  K. Chayama,et al.  Meta‐analysis of the effects of prokinetic agents in patients with functional dyspepsia , 2007, Journal of gastroenterology and hepatology.

[4]  W. Wong,et al.  Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Timothy P. L. Roberts,et al.  Gastric fundic distension activates fronto-limbic structures but not primary somatosensory cortex: A functional magnetic resonance imaging study , 2007, NeuroImage.

[6]  José V. Pardo,et al.  Functional neuroimaging of gastric distention , 2003, Journal of Gastrointestinal Surgery.

[7]  P. Dupont,et al.  Regional cerebral blood flow during gastric balloon distention in functional dyspepsia. , 2003, Gastroenterology.

[8]  J. Freston,et al.  Proton Pump Inhibitors: Effective First-Line Treatment for Management of Dyspepsia , 2007, Digestive Diseases and Sciences.

[9]  T. Ohkusa,et al.  Effect of a gastro‐protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: A double‐blind placebo‐controlled study in Japan , 2006, Journal of gastroenterology and hepatology.

[10]  S. Flier,et al.  Is Functional Dyspepsia of Particular Concern in Women? A Review of Gender Differences in Epidemiology, Pathophysiologic Mechanisms, Clinical Presentation, and Management , 2006, The American Journal of Gastroenterology.

[11]  E. Mayer,et al.  Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease , 2006, Alimentary pharmacology & therapeutics.

[12]  K. Hahm,et al.  Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. , 2006, World journal of gastroenterology.

[13]  Á. Pascual-Leone,et al.  Novel Therapeutic Approaches to the Treatment of Chronic Abdominal Visceral Pain , 2006, TheScientificWorldJournal.

[14]  M. Camilleri,et al.  Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. , 2006, Gastroenterology.

[15]  N. Talley,et al.  A placebo-controlled trial of itopride in functional dyspepsia. , 2006, The New England journal of medicine.

[16]  D. Forman,et al.  Pharmacological interventions for non-ulcer dyspepsia. , 2006, The Cochrane database of systematic reviews.

[17]  A. Zinsmeister,et al.  Functional dyspepsia, delayed gastric emptying, and impaired quality of life , 2005, Gut.

[18]  T. Ohkusa,et al.  Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review , 2005, Journal of Gastroenterology.

[19]  J. Vandenberghe,et al.  Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? , 2005, Gut.

[20]  M. Asaka,et al.  Randomized, double‐blind, placebo‐controlled crossover trial of famotidine in patients with functional dyspepsia , 2005, Alimentary pharmacology & therapeutics.

[21]  H. Seno,et al.  Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies , 2005, Alimentary pharmacology & therapeutics.

[22]  J. Tack,et al.  Pathophysiology and treatment of functional dyspepsia. , 2005, Journal of clinical gastroenterology.

[23]  G. Triadafilopoulos,et al.  A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  D. Amarapurkar,et al.  Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. , 2004, Journal of the Indian Medical Association.

[25]  D. Forman,et al.  The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. , 2004, Gastroenterology.

[26]  H. El‐Serag,et al.  The Prevalence and Risk Factors of Functional Dyspepsia in a Multiethnic Population in the United States , 2004, The American Journal of Gastroenterology.

[27]  F. Mearin,et al.  Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  P. Moayyedi,et al.  The methodological quality of trials affects estimates of treatment efficacy in functional (non‐ulcer) dyspepsia , 2004, Alimentary pharmacology & therapeutics.

[29]  D. Drossman Psychosocial Factors and the Disorders of GI Function: What is the Link? , 2004, American Journal of Gastroenterology.

[30]  N. Kinukawa,et al.  Treating Nonulcer Dyspepsia Considering Both Functional Disorders of the Digestive System and Psychiatric Conditions , 1998, Digestive Diseases and Sciences.

[31]  Chi-Sen Chang,et al.  Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. , 2003, Hepato-gastroenterology.

[32]  M. Yuen,et al.  Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients , 2002, Gut.

[33]  G. Holtmann,et al.  A randomized placebo‐controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia , 2002, Alimentary pharmacology & therapeutics.

[34]  R. Hunt Evolving concepts in the pathophysiology of functional gastrointestinal disorder. , 2002, Journal of clinical gastroenterology.

[35]  A. Morelli,et al.  Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia , 2002, Alimentary pharmacology & therapeutics.

[36]  J. Hartung,et al.  Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. , 2001, Scandinavian journal of gastroenterology.

[37]  N. Talley,et al.  Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis , 2001, American Journal of Gastroenterology.

[38]  M. Camilleri,et al.  Visceral hypersensitivity: facts, speculations, and challenges , 2001, Gut.

[39]  N. Talley,et al.  Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled trial , 2000, Alimentary pharmacology & therapeutics.

[40]  A. Blum,et al.  Short course acid suppressive treatment for patients with functional dyspepsia: results depend onHelicobacter pyloristatus , 2000, Gut.

[41]  V. Savarino,et al.  Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis , 2000, Alimentary pharmacology & therapeutics.

[42]  P. O'Malley,et al.  Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. , 2000, The American journal of medicine.

[43]  D. Drossman,et al.  Psychosocial aspects of the functional gastrointestinal disorders , 1999, Gut.

[44]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.

[45]  G. Tougas,et al.  Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. , 1999, The American journal of gastroenterology.

[46]  R. Fisher,et al.  Management of nonulcer dyspepsia. , 1998, The New England journal of medicine.

[47]  Talley,et al.  Efficacy of omeprazole in functional dyspepsia: double‐blind, randomized, placebo‐controlled trials (the Bond and Opera studies) , 1998, Alimentary pharmacology & therapeutics.

[48]  A. Andriulli,et al.  Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying , 1998, American Journal of Gastroenterology.

[49]  K. Olden Are psychosocial factors of aetiological importance in functional dyspepsia? , 1998, Bailliere's clinical gastroenterology.

[50]  M. Hughes,et al.  Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. , 1998, Journal of clinical gastroenterology.

[51]  J. Hyun,et al.  Effects of Levosulpiride in Patients with Functional Dyspepsia Accompanied by Delayed Gastric Emptying , 1998, The Korean journal of internal medicine.

[52]  S. Fullerton,et al.  Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. , 1998, The American journal of gastroenterology.

[53]  A. Sonnenberg,et al.  AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. , 1998, Gastroenterology.

[54]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[55]  M. Teh,et al.  Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: A double‐blind placebo‐controlled trial , 1997, Journal of gastroenterology and hepatology.

[56]  E A Mayer,et al.  Regional cerebral activity in normal and pathological perception of visceral pain. , 1997, Gastroenterology.

[57]  N. Talley,et al.  Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. , 1996, The American journal of gastroenterology.

[58]  U. Malt,et al.  A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. , 1996, Scandinavian journal of gastroenterology.

[59]  N. Talley Quality of life in functional dyspepsia. , 1996, Scandinavian journal of gastroenterology. Supplement.

[60]  O. Nyrén,et al.  Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. , 1995, Gastroenterology.

[61]  N. Talley Non‐ulcer dyspepsia: myths and realities , 1991, Alimentary pharmacology & therapeutics.

[62]  N. Talley Spectrum of chronic dyspepsia in the presence of the irritable bowel syndrome. , 1991, Scandinavian journal of gastroenterology. Supplement.

[63]  M. Comberlato,et al.  Drug Treatment of Functional Dyspepsia: A Meta‐Analysis of Randomized Controlled Clinical Trials , 1989, Journal of clinical gastroenterology.

[64]  MANAGEMENT OF DYSPEPSIA: REPORT OF A WORKING PARTY , 1988, The Lancet.

[65]  L. Miller,et al.  Dyspepsia, antral motor dysfunction, and gastric stasis of solids. , 1980, Gastroenterology.